|
1
|
Roychowdhury S and Caligiuri MA: Cytokine
therapy for cancer: Antigen presentation. Cancer Treat Res.
123:249–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kotredes KP and Gamero AM: Interferons as
inducers of apoptosis in malignant cells. J Interferon Cytokine
Res. 33:162–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gutterman JU: Cytokine therapeutics:
Lessons from interferon alpha. Proc Natl Acad Sci USA.
91:1198–1205. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lamm D, Brausi M, O'Donnell MA and Witjes
JA: Interferon alfa in the treatment paradigm for
non-muscle-invasive bladder cancer. Urol Oncol. 32:e21–e30. 2014.
View Article : Google Scholar
|
|
5
|
Whelan J, Patterson D, Perisoglou M,
Bielack S, Marina N, Smeland S and Bernstein M: The role of
interferons in the treatment of osteosarcoma. Pediatr Blood Cancer.
54:350–354. 2010. View Article : Google Scholar
|
|
6
|
Wang L, Jia D, Duan F, Sun Z, Liu X, Zhou
L, Sun L, Ren S, Ruan Y and Gu J: Combined anti-tumor effects of
IFN-α and sorafenib on hepatocellular carcinoma in vitro and in
vivo. Biochem Biophys Res Commun. 422:687–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Simonsson B, Hjorth-Hansen H, Bjerrum OW
and Porkka K: Interferon alpha for treatment of chronic myeloid
leukemia. Curr Drug Targets. 12:420–428. 2011. View Article : Google Scholar
|
|
8
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:e359–e386. 2015.
View Article : Google Scholar
|
|
9
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ramos MC, Mardegan MC, Tirone NR, Michelin
MA and Murta EF: The clinical use of type 1 interferon in
gynecology. Eur J Gynaecol Oncol. 31:145–150. 2010.PubMed/NCBI
|
|
11
|
Wang BX, Rahbar R and Fish EN: Interferon:
Current status and future prospects in cancer therapy. J Interferon
Cytokine Res. 31:545–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li X and Mao C: Using phage as a platform
to select cancer cell-targeting peptides. Methods Mol Biol.
1108:57–68. 2014. View Article : Google Scholar
|
|
13
|
Cao B, Yang M and Mao C: Phage as a
genetically modifiable supramacromolecule in chemistry, materials
and medicine. Acc Chem Res. 49:1111–1120. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin H, Chen N, Guo R, Wang H, Li W, Wang
G, Cui J, Jin H and Hu JF: Antitumor potential of a synthetic
interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in
pancreatic cancer cells. Sci Rep. 5:169752015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Chen N, Yin H, Zhang L, Li W, Wang
G, Cui J, Yang B and Hu JF: A placental growth factor-positively
charged peptide potentiates the antitumor activity of
interferon-gamma in human brain glioblastoma U87 cells. Am J Cancer
Res. 6:214–225. 2016.PubMed/NCBI
|
|
16
|
Sun J, Li W, Sun Y, Yu D, Wen X, Wang H,
Cui J, Wang G, Hoffman AR and Hu JF: A novel antisense long
noncoding RNA within the IGF1R gene locus is imprinted in
hematopoietic malignancies. Nucleic Acids Res. 42:9588–9601. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang H, Li W, Guo R, Sun J, Cui J, Wang G,
Hoffman AR and Hu JF: An intragenic long noncoding RNA interacts
epigenetically with the RUNX1 promoter and enhancer chromatin DNA
in hematopoietic malignancies. Int J Cancer. 135:2783–2794. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Choi HJ, Lui A, Ogony J, Jan R, Sims PJ
and Lewis-Wambi J: Targeting interferon response genes sensitizes
aromatase inhibitor resistant breast cancer cells to
estrogen-induced cell death. Breast Cancer Res. 17:62015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang G, Xu Y, Chen X and Hu G: IFITM1
plays an essential role in the antiproliferative action of
interferon-gamma. Oncogene. 26:594–603. 2007. View Article : Google Scholar
|
|
20
|
Khasraw M, Bell R and Dang C: Epirubicin:
Is it like doxorubicin in breast cancer? A clinical review Breast.
21:142–149. 2012.
|
|
21
|
Damiani RM, Moura DJ, Viau CM, Caceres RA,
Henriques JA and Saffi J: Pathways of cardiac toxicity: Comparison
between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch
Toxicol. 90:2063–2076. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chelbi-Alix MK and Wietzerbin J:
Interferon, a growing cytokine family: 50 years of interferon
research. Biochimie. 89:713–718. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Parker BS, Rautela J and Hertzog PJ:
Antitumour actions of interferons: Implications for cancer therapy.
Nat Rev Cancer. 16:131–144. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Szelag M, Piaszyk-Borychowska A,
Plens-Galaska M, Wesoly J and Bluyssen HA: Targeted inhibition of
STATs and IRFs as a potential treatment strategy in cardiovascular
disease. Oncotarget. 7:48788–48812. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Merches K, Khairnar V, Knuschke T,
Shaabani N, Honke N, Duhan V, Recher M, Navarini AA, Hardt C,
Häussinger D, et al: Virus-induced type I interferon deteriorates
control of systemic pseudomonas aeruginosa infection. Cell Physiol
Biochem. 36:2379–2392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heim MH and Thimme R: Innate and adaptive
immune responses in HCV infections. J Hepatol. 61(Suppl 1):
S14–S25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu Y, Jia H, Chen J, Cui G, Gao H, Wei Y,
Lu C, Wang L, Uede T and Diao H: Decreased osteopontin expression
as a reliable prognostic indicator of improvement in pulmonary
tuberculosis: impact of the level of interferon-gamma-inducible
protein 10. Cell Physiol Biochem. 37:1983–1996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao LJ, He SF, Liu Y, Zhao P, Bian ZQ and
Qi ZT: Inhibition of STAT pathway impairs anti-hepatitis C virus
effect of interferon alpha. Cell Physiol Biochem. 40:77–90. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takaoka A and Yanai H: Interferon
signalling network in innate defence. Cell Microbiol. 8:907–922.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Legrier ME, Bièche I, Gaston J, Beurdeley
A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL,
Vacher S, et al: Activation of IFN/STAT1 signalling predicts
response to chemotherapy in oestrogen receptor-negative breast
cancer. Br J Cancer. 114:177–187. 2016. View Article : Google Scholar :
|
|
31
|
Yang Y, Zhou Y, Hou J, Bai C, Li Z, Fan J,
Ng IOL, Zhou W, Sun H, Dong Q, et al: Hepatic IFIT3 predicts
interferon-α therapeutic response in patients of hepatocellular
carcinoma. Hepatology. Mar 13–2017.Epub ahead of print. View Article : Google Scholar
|
|
32
|
Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim
SE, Yap HL, Yeo WL, Tan P, Tan SH, et al: Chemotherapy-induced
tumor gene expression changes in human breast cancers.
Pharmacogenet Genomics. 19:181–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thomas M, Finnegan CE, Rogers KM, Purcell
JW, Trimble A, Johnston PG and Boland MP: STAT1: A modulator of
chemotherapy-induced apoptosis. Cancer Res. 64:8357–8364. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hannesdóttir L, Tymoszuk P, Parajuli N,
Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH,
Stoitzner P, et al: Lapatinib and doxorubicin enhance the
Stat1-dependent antitumor immune response. Eur J Immunol.
43:2718–2729. 2013. View Article : Google Scholar : PubMed/NCBI
|
